fig1

The impact of rituximab prophylaxis on hepatocellular carcinoma recurrence after living donor liver transplantation

Figure 1. Standard immunosuppressant protocol for ABO-I (A) from April 2006 to June 2009, (B) from July 2009 to July 2013, and (C) from August 2013. CPA: Cyclophosphamide; HA: hepatic artery; MMF: mycophenolate mofetil; MP: methylprednisolone; PE: plasma exchange; PGE1: prostaglandin E1; PV: portal vein; TAC: tacrolimus; PSL: prednisolone.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/